Medistim ASA MEDI
Oslo Børs · Healthcare · Medical Devices
306.00 NOK
+0.0%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Medistim
| NOK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 486 | 521 | 563 | 700 |
| EBITDA | 170 | 159 | 159 | 238 |
| Net income | 114 | 104 | 104 | 159 |
| Balance sheet | ||||
| Equity | 368 | 398 | 437 | 468 |
| Total debt | 17 | 18 | 34 | 49 |
| Cash | 144 | 146 | 171 | 206 |
| Net debt | −127 | −128 | −137 | −157 |
| Ratios and per share | ||||
| EBITDA margin | 34.9% | 30.6% | 28.3% | 34.0% |
| Profit margin | 23.4% | 19.9% | 18.5% | 22.8% |
| Return on equity | 31.0% | 26.1% | 23.8% | 34.0% |
| Earnings/share (NOK) | 6.24 | 5.68 | 5.67 | 8.71 |
| Book value/share (NOK) | 20.14 | 21.77 | 23.84 | 25.62 |
| Shares outstanding (M) | 18 | 18 | 18 | 18 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 35.1 |
| P/B | 11.9 |
| EV / EBITDA | 22.9 |
| Net debt / EBITDA | −0.7 |
| Return on equity | 34.0% |
| Profit margin | 22.8% |
| Beta 1Y | 0.19 |
| Revenue growth 1Y | +24.4% |
| Revenue CAGR 3Y | +12.9% |
| Earnings/share CAGR 3Y | +11.7% |
| ROE avg. 3Y | 28.0% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (NOK)
| 2026 | 10.50 |
| 2025 | 6.00 |
| 2024 | 4.50 |
| 2023 | 4.50 |
| 2022 | 3.75 |
Not investment advice. Figures may contain errors from the data source.